/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Kazia Therapeutics Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$12.92 0.3171(31.71%) KZIA at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 10.2
Highest Today 13.39
Today’s Open 10.255
Prev. Close 10.06
52 Week High 23.60
52 Week Low 2.86
Day’s Range: Low 10.2 High 13.39
52-Week Range: Low 2.86 High 23.60
1 day return -
1 Week return +23.97
1 month return +74.21
3 month return +63.65
6 month return +141.6
1 year return +181.7
3 year return +2001.25
5 year return +33.73
10 year return -

Institutional Holdings

Dauntless Investment Group, LLC 10.36

Barclays PLC 2.15

UBS Group AG 0.27

Rhumbline Advisers 0.05

GAMMA Investing LLC 0.02

SRS Capital Advisors Inc 0.02

Fidelity Nasdaq Composite Index 0.02

SBI Securities Co Ltd 0.01

Mccormack Advisors International 0.00

Advisor Group Holdings, Inc. 0.00

Hanson Mcclain Inc 0.00

Citigroup Inc 0.00

JPMorgan Chase & Co 0.00

Morgan Stanley - Brokerage Accounts 0.00

SIMPLEX TRADING, LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 16.81 M

PB Ratio 3.0866

PE Ratio 0.0

Enterprise Value 12.71 M

Total Assets 6.06 M

Volume 266443

Company Financials

Annual Revenue FY25:42000 0.0M, FY24:2308000 2.3M, FY23:0 0.0M, FY22:25 0.0M, FY21:15183000 15.2M

Annual Profit FY25:42000 0.0M, FY24:2308000 2.3M, FY23:null 0.0M, FY22:25 0.0M, FY21:15183000 15.2M

Annual Net worth FY25:-20702000 -20.7M, FY24:-26778000 -26.8M, FY23:-20465180 -20.5M, FY22:-24647815 -24.6M, FY21:-8422000 -8.4M

Quarterly Revenue Q4/2023:5 0.0M, Q3/2023:278 0.0M, Q2/2023:null 0.0M, Q1/2023:278 0.0M, Q4/2022:null 0.0M

Quarterly Profit Q4/2023:5 0.0M, Q3/2023:278 0.0M, Q2/2023:null 0.0M, Q1/2023:278 0.0M, Q4/2022:null 0.0M

Quarterly Net worth Q4/2023:-8823513 -8.8M, Q3/2023:-3439576 -3.4M, Q2/2023:null 0.0M, Q1/2023:-3439576 -3.4M, Q4/2022:-6793014 -6.8M

Fund house & investment objective

Company Information Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow